What is Hulio and who developed it?

Hulio is a biosimilar Adalimumab, and its global rights have been secured by Biocon Biologics from Fujifilm Kyowa Kirin Biologics.

What does Biocon Biologics gain with the new agreement?

Biocon Biologics gains full and exclusive global rights, along with end-to-end control over manufacturing and commercialization of Hulio.

How does this affect patient access to biologics?

This strategic move aims to enhance flexibility and cost efficiency, ultimately expanding affordable access to high-quality biologics for patients with inflammatory diseases.

Home / Business and Economy / Biocon Biologics Secures Global Rights for Hulio

Biocon Biologics Secures Global Rights for Hulio

23 Dec

•

Summary

Biocon Biologics now holds exclusive global rights for Hulio (biosimilar Adalimumab).
The company assumes full responsibility for manufacturing and commercialization.
This move enhances flexibility and aims to expand affordable access to biologics.

Biocon Biologics Secures Global Rights for Hulio

Biocon Biologics has finalized an agreement, securing complete and exclusive worldwide rights for Hulio, the biosimilar Adalimumab. This pivotal deal transfers end-to-end manufacturing and commercialization responsibilities to Biocon Biologics, along with authority for future development.

This new accord replaces the prior collaboration with Fujifilm Kyowa Kirin Biologics (FKB). While FKB will receive a technology license fee and royalties, they will also contribute to offsetting development costs. Commercial production will commence following successful technology transfer and regulatory approvals.

The strategic acquisition significantly enhances Biocon Biologics' operational flexibility and cost-effectiveness. This move underscores the company's commitment to increasing global access to high-quality, affordable biologics for patients managing inflammatory conditions.